Agree. At this point there is little to report on the commercial front. The only thing worth keeping an eye on is the expense / R&D line.
That said, I would like to see the company to start scheduling quarterly business updates. Even within the SEC constraints, I do believe that general updated on the state of the various trials and upcoming milestones would be welcomed by current and prospect shareholders.
I have been long since November of last year and have followed this and the YMB boards, paying particular attention to those who contribute on the science and the overall investment points of view. Over time I have accumulated a significant stake and firmly believe that if Dr. Missling continues to execute as he has, obviously the drug(s) need to do what we all expect, this could be one of the all-time medical and financial great stories. Just beginning to post and will do so if I believe I can add value. Otherwise, listening ot objectives points of view on both side of the isle.
Good luck!
News 
Market Data 
Discover 
AI
